A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs THR 317 (Primary) ; Ranibizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Oxurion
- 27 Apr 2018 Status changed from not yet recruiting to recruiting, according to a ThromboGenics media release.
- 27 Apr 2018 According to a ThromboGenics media release, initial results are anticipated in Q3 2019.
- 27 Apr 2018 According to a ThromboGenics media release, first patient has been enrolled.